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Consequently, I made further simple calculations based on
Table 2 in the study by Alsheikh-Ali et al. (1). There was a
significant correlation between achieved LDL and cancer per
100,000 person-years (r  0.75, p  0.003), but also between
mean age in trials (median age 65 years for the HPS [Heart
Protection Study]) and cancer incidence (r  0.82, p  0.0006).
This is naturally expected as cancer risk increases with age. In
multivariate analyses, adjusted for sample size, achieved LDL was
a significant predictor of cancer incidence (p  0.03). However,
when age was included in the model, age (p  0.008)—but not
achieved LDL (p  0.42)—was a significant predictor of cancer
risk.
I think that these findings, together with totality of evidence
including data from the TNT (Treating to New Targets) study (2)
and also from the IDEAL (Incremental Decrease in Clinical
Endpoints Through Aggressive Lipid Lowering) study (3), at this
stage refute a true link between achieved LDL and cancer risk.
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Reply
Drs. Rembold and Strandberg appropriately raise the possibility
of confounding by age as an explanation for the observed
association between achieved low-density lipoprotein choles-
terol (LDL-C) and incident cancer (1). To properly address
that possibility, we performed a more comprehensive analysis
including all the trials in the original study with the addition of
5 large randomized statin trials where incident cancer was
reported (Post-CABG [Post Coronary Artery Bypass Graft],
GISSI—Prevenzione [Gruppo Italiano per lo Studio della
Sopravvivenza nell’Infarto Miocardico—Prevention], Kyushu
Lipid Intervention, ALERT [Assessment of Lescol in Renal
Transplantation], and MEGA [Management of Elevated Cho-
lesterol in the Primary Prevention Group of Adult Japanese])
(2– 6). Furthermore, the analysis we performed was weighted
and used a random-effects model given the heterogeneity of
the trials involved. This more appropriate and comprehensive
analysis yields a significant univariate association between age
and incident cancer (p  0.031) as well as a significant inverse
univariate association between achieved LDL-C and cancer
(p  0.006). When age and achieved LDL-C are combined in
a multivariate model, the inverse association between achieved
LDL-C and cancer persists (p  0.021), whereas that between
age and cancer loses statistical significance (p  0.110). This
suggests that the association between achieved LDL-C and
cancer is not confounded by age, a finding consistent with
previous epidemiologic observations (7). Dr. Kjekshus suggests
excluding deaths within the first year after onset of statin
treatment to test the hypothesis that the observed relationship
is dependent on an association between incipient cancer and low
levels of LDL-C. Although such an analysis would be infor-
mative, we are unable to perform it because we have no access
to individual patient data or dates of cancer diagnoses. Further-
more, it is worth noting that the association between low
cholesterol and cancer deaths in the epidemiologic literature
persisted after excluding deaths occurring in the first 5 years
after measuring cholesterol levels (7). We also agree that a
comparative analysis including the placebo groups would be
informative, and this is part of ongoing analyses to better
understand the association between LDL-C and cancer.
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